A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
A phase 1/2 trial of Atezolizumab, Ifinatamab deruxtecan in small-cell lung cancer, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), active and no longer recruiting.
Overview
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) is a phase 1/2 interventional study registered as NCT04471727 by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), with 232 participants planned, started 2020-12-14 and due to reach its primary completion in 2028-01-28. Interventions recorded: Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd). Conditions listed: Small-Cell Lung Cancer, Neuroendocrine Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-
Shares Ifinatamab deruxtecan, Atezolizumab, Small-cell lung cancer.
- TrialA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Shares Ifinatamab deruxtecan, Atezolizumab, Small-cell lung cancer.
- TrialIfinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- TrialA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv
- TrialA Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Shares Atezolizumab, Small-cell lung cancer.
- TrialA Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Shares Atezolizumab, Small-cell lung cancer.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Atezolizumab, Small-cell lung cancer.
- TrialQuaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Shares Atezolizumab, Small-cell lung cancer.